Summer 2026 – Undergraduate Induced Proximity Innovation, Protein Homeostasis TRC Internship at Bristol-Myers Squibb

San Diego, California, United States

Apply Now

Not SpecifiedCompensation

InternshipExperience Level

InternshipJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Enrolled in a bachelor’s degree program majoring in Biology (e.g. Cell Biology, Molecular Biology), Biochemistry, or related discipline
Completed at least 2 years of study towards their Bachelor’s degree
Strong communication skills (written and verbal), and the ability to work in a collaborative environment
Demonstrate interest in oncology research and drug discovery
Basic laboratory skills (from lab courses or work in research), and experience with mammalian cell culture is preferred but not required
Authorized to work in the US at the time of hire
Basic understanding of molecular & cell biology and a strong desire to learn about new approaches for therapeutic intervention

Responsibilities

Gain background knowledge of the assigned project by reading scientific literature
Work with program scientists to understand experimental design and execution
Learn and perform laboratory techniques required for project completion
Meet with scientific advisors on a regular basis to review progress
Maintain documentation of experiments in an electronic lab notebook
Attend project/group meetings and learn about programs for drug development
Analyze experimental data and present project findings at the conclusion of the program

Skills

molecular biology

protein homeostasis

induced proximity

E3 ubiquitin ligases

targeted protein degradation

biology research

drug discovery

STEM

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free